MBX Capital
SelectiveFiled to raiseClaymont, DEBiotech & pharmaLast fund filed 2025
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| MBX Capital NYS SSBCI FundFiled to raise in 2025, with no closing reported yet. | 2025 | $6M | $0 | 0 |
| MBX Capital III-A | August 2023 | $1.4M | $1.4M | 12 |
| MBX CAPITAL IIIFiled to raise in 2023, with no closing reported yet. | 2023 | $50M | $0 | 0 |
| MBX Capital II-A | 2022 | $4.5M | $4.5M | 33 |
| MBX CROSSOVER CAPSULE I | May 2021 | $4.1M | $4.1M | 80 |
| MBX Capital IIFiled to raise in 2021, with no closing reported yet. | 2021 | $30M | $0 | 0 |
| FRx Select IFiled to raise in 2018, with no closing reported yet. | 2018 | $25M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Gurdane Bhutani | Selective | Biotech & pharma | 5 | 2 |
| Zeshan Muhammedi | Quiet | None listed | 2 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Too few companies classified yet to infer a focus. 1 of 6 portfolio companies are classified.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of MBX Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Advent Life Sciences | 1 | Ancilia Biosciences |
A shared board seat: a company where filings name a MBX Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.